For citations:
Mazina N.K., Mazin P.V. Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2017;10(3):12-21. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.3.012-021
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 